Why more CDMOs are rethinking column packing at clinical scale

For CDMOs running monoclonal antibody and cell and gene therapy programs at clinical scale, downstream teams are rarely working on just one process. Programs overlap, and timelines compress quickly between late development and GMP readiness. Sponsors expect speed, but they also expect clean, reproducible data.

In this environment, chromatography columns influence more than process performance, they influence delivery credibility.

When internal packing starts to show its limits

For many mAb programs, column packing is still done in-house to generate GMP-relevant data. It can work well, but as programs move forward, small differences begin to matter.

Variations in slurry preparation, compression, operators, or flow distribution may seem minor, yet over time they can show up in performance data. When comparability packages are being built and clinical supply depends on reproducibility, that variability becomes more than a technical detail. It introduces uncertainty into timelines and client confidence.

At the same time, CDMOs and downstream teams are often stretched across multiple client programs. Packing and repacking columns takes time and experienced resource. As column diameters increase to bridge into pilot manufacturing, packing becomes more sensitive and reproducibility harder to maintain consistently across operators. The pressure builds quietly, turnaround times extend, and internal capacity tightens. The focus shifts from optimizing the purification process to managing packing variability.

Scale progression in CGT adds another layer

For CGT programs entering clinical stages, the challenge is just as significant. Viral vector processes are often sensitive to pressure and shear. The resin has already been selected, and the task becomes scaling reliably, without introducing new variability.

Scaling column diameters quickly, while maintaining consistent performance, adds operational strain. Any delay can impact sponsor milestones, and any inconsistency can affect future work. Reproducible packing and flexible hardware are not simply technical preferences, they are timeline protection tools.

Why pre-packed is becoming a strategic choice

For CDMOs, what matters most is not whether a column is pre-packed, but whether that decision protects schedules, margins, and client relationships. Lead time is a good example. Many standard pre-packed options come with extended delivery windows and limited responsiveness and flexibility once specifications are confirmed. For CDMOs operating against fixed manufacturing slots and sponsor-driven milestones, an additional 6 to 8 weeks is not a small delay. It compresses tech transfer, strains internal teams, and can put revenue and client confidence at risk.

This is where responsiveness matters as much as packing quality.

Astrea Bioseparations’ Evolve®D pre-packed columns are designed for pilot to clinical scale purification, with a focus on reproducible, right-first-time packing and fast, dependable turnaround. The aim is straightforward: reduce the operational burden on downstream teams while maintaining consistent performance as column diameters scale.

In practice, that means:

• Campaign-ready columns when you need them
• Reduced variability introduced at the packing stage
• Greater confidence when bridging development into pilot manufacturing
• More predictable clinical execution across multiple client programs

When column supply is consistent and reliable, it becomes easier to protect timelines, safeguard data integrity, and maintain sponsor trust. At clinical scale, that consistency is not a convenience, it’s part of how CDMOs compete.

Looking to take column packing off your team’s plate? Learn how Astrea Bioseparations can help with reliable, consistent column packing, in as little as 21 days.